Sexual Wellness & Peptides: Libido, Hormones & What Science Actually Supports

Destigmatizing Sexual Wellness in Mainstream Health

For decades, sexual health occupied a peculiar blind spot in wellness culture. Topics like gut health, sleep optimization, and metabolic function attracted serious editorial treatment. Sexual function got hushed conversations and euphemistic supplement ads.

That's changing — and for good reasons rooted in biology, not culture wars. The World Health Organization defines sexual health as "a state of physical, emotional, mental and social well-being in relation to sexuality" and explicitly states it is not merely the absence of disease. The endocrine system, cardiovascular system, and nervous system all converge in sexual function. When something goes wrong in that domain, it frequently signals problems elsewhere.

The longevity medicine community has been particularly clear about this. Sexual function correlates with cardiovascular health, hormonal integrity, metabolic fitness, neurological function, and psychological wellbeing. Treating it as a separate, stigmatized topic makes as much clinical sense as ignoring blood pressure because it's "personal."

This article treats sexual wellness exactly like any other wellness topic: with specificity, evidence, and a total absence of awkwardness. If you can read about GHK-Cu collagen stimulation or GLP-1 receptor agonism without blushing, you can read about melanocortin receptors and hypothalamic signaling.

Libido as a Health Biomarker

Libido is not just about sex. It's a composite readout of your endocrine system, neurological health, stress load, sleep quality, and metabolic function. When clinicians encounter a patient with unexplained loss of sexual desire, they don't just refer to a sex therapist — they order labs. Because low libido is a symptom, and symptoms have causes.

What Low Libido Can Signal

• Hormonal deficiency — Low testosterone (men and women), estrogen decline (perimenopause/menopause), thyroid dysfunction, elevated prolactin
• Cardiovascular dysfunction — Erectile dysfunction in men is now recognized as an early marker of endothelial dysfunction, often preceding cardiovascular events by 3–5 years
• Metabolic syndrome — Insulin resistance, obesity, and type 2 diabetes all directly suppress sexual function through multiple hormonal and vascular pathways
• Chronic stress & HPA axis dysregulation — Elevated cortisol directly suppresses GnRH pulsatility, reducing testosterone and estrogen production
• Medication side effects — SSRIs, beta-blockers, statins, antihistamines, and hormonal contraceptives all have documented effects on libido
• Depression and anxiety — Both conditions independently reduce sexual desire, separate from any medication effects
• Sleep disorders — Sleep apnea alone can reduce testosterone by 10–15%; chronic sleep deprivation suppresses it further

The European Association of Urology's 2024 guidelines specifically recommend sexual function assessment as part of routine men's health screening after age 40. For women, ACOG recommends sexual health screening at all annual exams. The clinical consensus is clear: sexual function is a vital sign.

Testosterone, Estrogen & the Balance That Matters

Hormones are the foundation of sexual function. Not the only factor — psychology, relationship quality, and neurochemistry all contribute — but the hormonal substrate must be intact. When it isn't, everything else becomes harder to optimize.

Testosterone: Not Just a Male Hormone

Testosterone is the primary driver of sexual desire in both men and women. In men, total testosterone below approximately 300 ng/dL is generally considered clinically low, though symptoms can appear at higher levels depending on free testosterone, SHBG levels, and individual sensitivity.

In women, testosterone is produced in smaller quantities by the ovaries and adrenal glands, but its role in libido is equally critical. Women with surgically removed ovaries experience dramatic testosterone drops and correspondingly sharp declines in sexual desire — often restored with low-dose testosterone replacement.

Age-related testosterone decline is real. Men lose approximately 1–2% per year after age 30. Women experience a steeper hormonal transition during perimenopause and menopause. For a deeper comparison of testosterone approaches, see our guide on Peptides vs SARMs vs TRT.

Estrogen: The Complexity Factor

Estrogen's relationship with sexual function is nuanced. In premenopausal women, estrogen maintains vaginal tissue health, lubrication, and blood flow — all necessary for comfortable, enjoyable sexual function. Estrogen decline during menopause causes vaginal atrophy, dryness, and pain (genitourinary syndrome of menopause, or GSM), which suppresses desire secondarily.

In men, estrogen (produced via aromatization of testosterone) plays a role in libido, bone health, and cardiovascular function. Both excessively low and excessively high estradiol levels in men correlate with reduced sexual function — the optimal range is 20–40 pg/mL for most men, though individual variation exists.

PT-141 (Bremelanotide): How It Works

PT-141, sold under the brand name Vyleesi, is the first and only FDA-approved peptide for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Its approval in 2019 marked a significant moment in sexual medicine — the first time a centrally-acting (brain-targeted) drug was approved specifically for low desire.

Mechanism of Action

PT-141 is an agonist of the melanocortin-4 receptor (MC4R), primarily in the hypothalamus and limbic system. This is fundamentally different from PDE5 inhibitors like sildenafil (Viagra) or tadalafil (Cialis), which act peripherally on blood vessel smooth muscle to improve erection mechanics.

PT-141 works upstream — it activates the neural pathways involved in sexual desire and arousal at the brain level. It can increase desire even without physical sexual stimulation. The melanocortin system is the same neuropeptide family involved in skin pigmentation (Melanotan I and II act on related receptors — see our Melanotan guide for that angle), appetite regulation, and stress response.

Clinical Evidence

The FDA approval was based on two Phase III trials (RECONNECT studies) involving over 1,200 premenopausal women with HSDD. Key findings:

• Statistically significant increase in desire and reduction in distress related to low desire versus placebo
• Approximately 25% of women experienced a meaningful increase in desire (vs. ~17% on placebo)
• Effects are acute — administered ~45 minutes before anticipated sexual activity via subcutaneous injection
• Not intended for daily use; FDA recommends no more than 8 doses per month

Off-Label Use in Men

PT-141 has been studied off-label in men with erectile dysfunction, particularly those who don't respond to PDE5 inhibitors. Early clinical data (Phase II) showed improvements in erectile function, but the evidence base is significantly smaller than for women. The mechanism is plausible — MC4R is expressed in male brain regions involved in sexual function — but rigorous Phase III data in men is lacking.

PT-141 vs Other Sexual Health Treatments

Peptides & Sexual Health: Kisspeptin, GnRH Analogs & the Neuroendocrine Axis

PT-141 is the most clinically developed sexual health peptide, but it's not the only one in the research pipeline. Several peptides interact with the neuroendocrine systems governing sexual function. Understanding these helps clarify where the field is heading. For a comprehensive breakdown of how PT-141 works, what the clinical trials actually showed, and the nasal spray vs. injection debate, see our full editorial: PT-141 (Bremelanotide/Vyleesi): The FDA-Approved Libido Peptide — What the Science Says.

Kisspeptin

Kisspeptin is a neuropeptide produced in the hypothalamus that acts as the master switch for the HPG (hypothalamic-pituitary-gonadal) axis. It stimulates GnRH neurons to release gonadotropin-releasing hormone, which triggers LH and FSH secretion from the pituitary, which drives testosterone and estrogen production in the gonads.

What makes kisspeptin particularly interesting for sexual health is that it appears to bridge hormonal and psychological arousal. Research published in the Journal of Clinical Investigation (Dhillo et al., 2017) showed that kisspeptin administration increased brain responses to sexual stimuli on fMRI, enhanced penile tumescence, and improved self-reported sexual desire in healthy men. A separate study in women (Comninos et al., 2021) found that kisspeptin enhanced brain processing of sexual and romantic stimuli.

Kisspeptin is currently in clinical research. It is not FDA-approved for any therapeutic use, but its dual role — stimulating both hormone production and neural desire pathways — makes it one of the most promising candidates for future sexual health therapies.

GnRH Analogs (Pulsatile vs Continuous)

GnRH (gonadotropin-releasing hormone) itself is a peptide, and its analogs are already used therapeutically — though context matters enormously. Pulsatile GnRH administration mimics natural hypothalamic signaling and stimulates testosterone/estrogen production. Continuous GnRH agonist administration (as in leuprolide) paradoxically suppresses the axis after an initial flare — used in prostate cancer, endometriosis, and precocious puberty.

For sexual health specifically, pulsatile GnRH protocols are being explored as an alternative to direct testosterone replacement in men with secondary hypogonadism (where the problem is in the brain's signaling, not the testes themselves). This approach preserves fertility — a significant advantage over exogenous testosterone, which suppresses sperm production.

Melanotan II and the MC4R Connection

PT-141 was actually derived from Melanotan II research. Melanotan II, originally developed for skin tanning, was found to have pronounced effects on sexual arousal — an unexpected side effect that led to the development of PT-141 as a more targeted MC4R agonist. Unlike Melanotan II, PT-141 has minimal tanning effects because it was engineered for receptor selectivity.

Lifestyle Factors: Sleep, Stress & Exercise

Before reaching for any peptide or supplement, the evidence is clear that lifestyle factors are the single largest modifiable influence on sexual function. This isn't the "drink more water" advice you skip past — these interventions have effect sizes comparable to or exceeding pharmacological treatments.

Sleep

Testosterone production is heavily sleep-dependent. The majority of daily testosterone secretion occurs during sleep, particularly during REM phases. A landmark University of Chicago study (Leproult & Van Cauter, 2011) found that one week of sleep restriction to 5 hours per night reduced testosterone by 10–15% in young healthy men — equivalent to aging 10–15 years hormonally.

Sleep apnea is particularly destructive. Repeated hypoxic events suppress the HPG axis, reduce testosterone, and impair nocturnal erections. Treatment of sleep apnea with CPAP has been shown to partially restore testosterone levels and improve sexual function in multiple studies.

Stress & Cortisol

The HPA (hypothalamic-pituitary-adrenal) axis and the HPG axis are antagonistic. When cortisol is chronically elevated, GnRH pulsatility is suppressed, LH output drops, and downstream sex hormone production falls. This is not metaphorical — it is a directly measurable hormonal cascade.

Chronic psychological stress, overtraining, undereating, and sleep deprivation all elevate cortisol. The intervention is straightforward conceptually (reduce stressors, improve recovery) but often requires deliberate structural changes: protecting sleep, managing workload, and incorporating genuine recovery practices — not just meditation apps.

Exercise

Regular resistance training is one of the most evidence-supported interventions for testosterone optimization. A meta-analysis in Sports Medicine (Riachy et al., 2020) confirmed that resistance training consistently increases both acute and resting testosterone levels in men. Compound movements (squats, deadlifts, presses) with moderate-to-heavy loads and adequate recovery produce the strongest hormonal responses.

However, there is a dose-response curve with a clear ceiling. Overtraining syndrome — excessive volume without adequate recovery — suppresses testosterone through cortisol elevation and energy deficit. Endurance athletes who train at very high volumes frequently present with low testosterone, amenorrhea (in women), and reduced libido.

Supplements & Adaptogens: What Evidence Actually Says

The supplement industry markets aggressively toward sexual function, and most claims outpace the evidence. Here is an honest assessment of the compounds with actual clinical data — and those that are mostly marketing.

Ashwagandha (Withania somnifera)

Evidence level: Moderate (multiple RCTs)

Ashwagandha has the strongest evidence base of any adaptogen for sexual health. A 2015 RCT (Ambiye et al.) found that 600 mg/day of KSM-66 ashwagandha root extract for 8 weeks significantly improved testosterone levels, sperm parameters, and sexual function scores in men compared to placebo. A separate 2015 study in women (Dongre et al.) found improvements in arousal, lubrication, orgasm, and satisfaction scores with 300 mg twice daily over 8 weeks.

The mechanism is likely indirect: ashwagandha is a well-documented cortisol-lowering adaptogen. By reducing chronic cortisol, it may remove the HPA axis brake on HPG axis function, allowing testosterone and other sex hormones to normalize. This is not the same as directly boosting testosterone — it's removing an inhibitor.

Maca (Lepidium meyenii)

Evidence level: Moderate-weak (small RCTs, mixed results)

Maca has a traditional reputation as a libido enhancer in Peruvian medicine. Clinical data is mixed but directionally positive. A 2002 RCT (Gonzales et al.) found improvements in self-reported sexual desire at 8 and 12 weeks with 1.5–3 g/day, without changes in serum testosterone or estradiol. This suggests a mechanism independent of the hormonal axis — possibly involving neurotransmitter modulation or placebo effects.

A 2015 systematic review (Shin et al.) concluded that maca "may have a positive effect on sexual dysfunction," but noted that sample sizes were small and methodological quality was limited. It is generally well-tolerated, with minimal side effects. The gelatinized (heat-treated) form is better tolerated gastrointestinally.

Tongkat Ali (Eurycoma longifolia)

Evidence level: Moderate (several RCTs, plausible mechanism)

Tongkat ali has been studied for effects on testosterone, cortisol, and sexual function. A 2012 RCT (Talbott et al.) found that 200 mg/day of a standardized extract for 4 weeks improved salivary testosterone by 37% and reduced cortisol by 16% in moderately stressed adults. A 2014 study in older men with hypogonadism found that 200 mg/day improved testosterone levels sufficiently to bring some participants above the clinical threshold.

The proposed mechanism involves inhibition of aromatase (reducing testosterone conversion to estrogen) and release of bound testosterone from SHBG. These are plausible mechanisms but not definitively established. Quality and standardization of tongkat ali products vary significantly.

What's Mostly Marketing

• Tribulus terrestris — Despite being the most marketed "testosterone booster," systematic reviews consistently find no significant effect on testosterone in humans. The animal data does not translate.
• Fenugreek — Limited evidence of modest effects on sexual function, but the testosterone-boosting claims are not well-supported by robust RCTs.
• Horny goat weed (epimedium) — Contains icariin, a weak PDE5 inhibitor. The concentrations in supplements are far below pharmacologically active levels. Traditional use predates evidence-based evaluation.
• DHEA supplements — DHEA is a real precursor to sex hormones, but supplementation effects are inconsistent and dose-dependent. May benefit women over 40 with documented DHEA-S deficiency; less convincing in younger populations or men. Requires lab monitoring.

When to See a Specialist

Self-optimization has limits. Here are the clear indicators that you should consult a medical professional rather than continuing to troubleshoot on your own.

See a Doctor If:

• Sustained libido decline (>2–3 months) without an obvious cause (new medication, major stressor, sleep disruption)
• Erectile dysfunction that doesn't improve with lifestyle changes — especially in men under 50, where it may signal vascular disease
• Pain during intercourse (dyspareunia) — always warrants medical evaluation
• Hormonal symptoms alongside sexual dysfunction — fatigue, unexplained weight gain/loss, hair loss, mood changes, hot flashes, night sweats
• Post-surgical or post-medication changes — particularly after prostate surgery, hysterectomy, or starting new medications
• Mental health impact — when sexual dysfunction is causing significant distress, relationship strain, or depression

Which Specialist?

• Endocrinologist — For comprehensive hormone evaluation and management. Best first stop if you suspect hormonal causes.
• Urologist — For men with erectile dysfunction, prostate concerns, or fertility issues.
• Gynecologist — For women with hormonal changes, menopause management, or pain concerns.
• Sexual medicine specialist — Increasingly available, these providers specialize in the intersection of hormonal, psychological, and physical sexual health.
• Functional/integrative medicine — For comprehensive approaches incorporating lifestyle, nutrition, and targeted supplementation. Ensure the provider is board-certified.

What Labs to Request

If your provider isn't sure where to start, a useful baseline panel includes:

• Total and free testosterone (men and women)
• Estradiol (E2)
• SHBG (sex hormone-binding globulin)
• LH and FSH
• Prolactin
• DHEA-S
• Thyroid panel (TSH, free T3, free T4)
• Fasting insulin and HbA1c (metabolic markers)
• Complete blood count and comprehensive metabolic panel

Sexual Health & Longevity: The Research Connection

This is where sexual wellness connects to the broader longevity conversation — and the data is more compelling than many people expect.

Sexual Frequency and Mortality

A widely-cited longitudinal study from Caerphilly, Wales (Davey Smith et al., 1997) followed 918 men over 10 years and found that men reporting higher orgasm frequency had a 50% lower mortality risk compared to those with the lowest frequency, after adjusting for age and other risk factors. Subsequent studies have found similar associations, though causality is debated — healthier people may simply have more sex, rather than sex making them healthier.

Hormonal Health and Aging

Testosterone levels in men predict all-cause mortality. Multiple large cohort studies (including the European Male Aging Study) have found that men in the lowest testosterone quartile have significantly higher cardiovascular and all-cause mortality. This does not prove that raising testosterone extends life — but it establishes that hormonal health and longevity track together.

In women, earlier menopause (and earlier loss of endogenous estrogen) is associated with increased cardiovascular risk, osteoporosis, and cognitive decline. Hormone replacement therapy, when initiated in the "window of opportunity" (within 10 years of menopause), has been shown to reduce all-cause mortality in multiple studies, including the Danish Osteoporosis Prevention Study.

The Broader Pattern

Sexual function is not an isolated system. It is a composite output of cardiovascular health, hormonal integrity, metabolic fitness, neurological function, and psychological wellbeing. When sexual function declines, it is rarely because the "sex system" broke — it's because one or more of these foundational systems is struggling.

This is why longevity physicians increasingly include sexual function in their assessment frameworks alongside VO2 max, grip strength, metabolic panels, and cognitive testing. It is another window into systemic health — and one that patients are often more motivated to optimize than their HbA1c.

The Bottom Line

Sexual health deserves exactly the same rigor, specificity, and destigmatized attention as any other domain in wellness. The biology is clear: libido is a biomarker, hormones are foundational, and peptides like PT-141 represent a genuinely novel approach to desire — central-acting rather than peripheral, addressing the "want to" rather than just the "can."

The evidence hierarchy is also clear. Lifestyle first (sleep, stress management, exercise, body composition), then medical evaluation (hormone panels, underlying conditions), then targeted interventions (hormone optimization, peptides like PT-141 or emerging options like kisspeptin), with supplements as adjuncts — not replacements for the foundational work.

Ashwagandha and tongkat ali have genuine evidence. Tribulus does not. PT-141 is FDA-approved for a specific indication. Kisspeptin is promising but not yet available outside research settings. Testosterone optimization requires medical supervision and individualized protocols, not internet forums.

And if something has changed — if desire has dropped without explanation, if function isn't what it was, if the usual interventions aren't working — see a specialist. Not because something is "wrong with you," but because your body is telling you something worth listening to.

For more on the peptide landscape, start with our Peptides 101 Guide. For hormone-related questions about testosterone therapies, read Peptides vs SARMs vs TRT. And if you have a specific question, the WellSourced Q&A community is here.